The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products.

Priovant’s once-daily JAK/TYK2 inhibitor introduces a new FDA-approved treatment option for the rare autoimmune disease, supported by Phase III evidence of improvements across muscle, skin and physical-function measures.

The once-daily combination of bictegravir and lenacapavir offers virologically suppressed adults a new route to simplify treatment, including patients previously requiring complex multi-tablet regimens.

The updated Comirnaty formulation targets the XFG variant and will begin shipping immediately for eligible older adults and people aged five to 64 at increased risk of severe COVID-19.

The latest regulatory package is intended to reduce uncertainty, development costs and delays for generic manufacturers as the US government increases pressure to bring lower-cost medicines to patients more quickly.

The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders.

BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions.

The commercial partnership combines 4basebio’s cell-free hpDNA platform with Genezen’s viral vector CDMO capabilities to provide cell and gene therapy developers with an alternative to conventional plasmid DNA manufacturing.

The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

The acquisition moves Switchboard beyond specialty-care navigation into direct care delivery by integrating Livara’s virtual-first, value-based MSK model, alongside more than $5 million in new financing.

The collaboration will establish a START clinical trial site inside AHN’s Allegheny General Hospital, connecting patients across the region with START’s portfolio of nearly 1,000 active early-phase oncology studies.

The reimbursement decision clears the way for Irish patients with Friedreich’s ataxia to access the first treatment for the rare neurological disease, following prolonged negotiations over cost and clinical value.

The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers.

The conditional marketing approval introduces a new intravenous abatacept biosimilar for patients with moderate to severe rheumatoid arthritis or active psoriatic arthritis who have responded inadequately to other disease-modifying treatments.

The approvals introduce zanidatamab-based first-line options for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma, with treatment determined by HER2 status.

The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.

The acquisition adds clinical research, biomarker, laboratory, market access and commercialisation capabilities to McKesson’s Oncology & Multispecialty business, extending its services across the drug-development pathway.

The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.

Meiji Seika Pharma group company KM Biologics and Serum Institute of India (SII) are collaborating to transfer technology for the development and manufacture in India of the Japanese encephalitis vaccine currently produced and marketed by KM Biologics in Japan. SII is expected to seek Indian regulatory approval as early as 2027, with the partnership intended to establish local manufacturing and supply of the vaccine for children in India.

The approval extends Johnson & Johnson’s FcRn-blocking therapy into wAIHA, providing a new targeted treatment for adults with a rare autoimmune blood disorder that can cause severe and persistent haemolytic anaemia.